Hospitals should choose antibiotic injections using a structured escalation pathway involving Ceftriaxone injection (Inj. GenCeft 1gm/2gm), Cefoperazone-Sulbactam injection (Inj. GenCepS 1.5gm / Inj. GenCepS Forte 3gm), Piperacillin-Tazobactam injection (Inj. GenPiptaz 4.5gm), and Meropenem injection (Inj. GenMero 500mg / 1gm).
Full 7 Injection Clinical Framework
| Clinical Level | Antibiotic Injection | Brand |
| Initial mild infection | Ceftriaxone injection | Inj. GenCeft 1gm |
| Moderate infection | Ceftriaxone injection | Inj. GenCeft 2gm |
| Moderate escalation | Cefoperazone-Sulbactam injection | Inj. GenCepS 1.5gm |
| Severe escalation | Cefoperazone-Sulbactam injection | Inj. GenCepS Forte 3gm |
| Empirical ICU therapy | Piperacillin-Tazobactam injection | Inj. GenPiptaz 4.5gm |
| Controlled escalation | Meropenem injection | Inj. GenMero 500mg |
| Critical infection | Meropenem injection | Inj. GenMero 1gm |
How These Injections Work Together
- Start → Inj. GenCeft
- Escalate → Inj. GenCepS / Forte
- Broaden → Inj. GenPiptaz
- Control → Inj. GenMero
Insight
These are not competing injections.
They are a connected clinical decision system.
Operational Gap
- No escalation tracking
- No usage visibility
- No rate consistency
Loss
- Overuse of high-end injections
- Underutilization of base-level injections
- Procurement inconsistency
Our Mission
To structure daily antibiotic injection decisions.
Our Vision
To ensure every injection—from Inj. GenCeft to Inj. GenMero—
is used within a clear and measurable system
Ecosystem Layer
A structured system enables:
- Tracking of all injections and medical supply
- Rate comparison
- Visibility of escalation
- Reduction in expiry
Business Model Clarity
Hospitals are not charged to use the system.
Value is created through structured antibiotic injection usage.
Conclusion
Better outcomes come from structured use of Medical Supply, not just availability.